TOFACITINIB FOR THE TREATMENT OF ULCERATIVE COLITIS: AN UPDATE ON THE ANALYSIS OF MALIGNANCY RATES FROM THE ULCERATIVE COLITIS CLINICAL PROGRAMME AS OF MAY 2019

Gary Lichtenstein  ¹     Matthew A. Ciorba  ²     Gerhard Rogler  ³     Ala Sharara  ⁴     Nancy Sunna  ⁵     Rajiv Mundayat  ⁶     Donna T Judd  ⁷     Nervin Lawendy  ⁷     Julian Panés  ^8    
1 Perelman School of Medicine at the University of Pennsylvania, Philadelphia, United States
² Washington University in St. Louis, St. Louis, United States
³ University of Zürich, Zürich, Switzerland
⁴ American University of Beirut Medical Center, Beirut, Lebanon
⁵ Pfizer, Amman, Jordan
⁶ Pfizer Inc, New York, United States
⁷ Pfizer Inc, Collegeville, United States
⁸ Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain

Topic
IBD

Session
IBD: Clinical trials II

Conference
UEG Week Virtual 2020

Citation
United European Gastroenterology Journal 2020; 8 (Supplement 1)